168 related articles for article (PubMed ID: 38477529)
1. A nomogram based on TFE3 IHC results and clinical factors as a preliminary screening scheme for TFE3-rearranged renal cell carcinoma.
Li P; Xu Q; Chen M; Zhu J; Wang Y; Mumin MA; Huang K; Jiang Z; Liang H; Deng Q; Wang Z; Liao B; Chen W; Cao Y; Cao J; Luo J
Cancer Med; 2024 Mar; 13(5):e6813. PubMed ID: 38477529
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic strategies and predictive models for Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma in adults based on data of two Chinese medical centers.
Yang Y; Zhao C; Wang Z; Liu F; Zhao M; Yang H; Chen J; Chen X; Shi M; Jiang D; Luo X; Duan Y; Bai Y
Aging (Albany NY); 2024 Jan; 16(2):1696-1711. PubMed ID: 38261736
[TBL] [Abstract][Full Text] [Related]
3. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey.
Akgul M; Williamson SR; Ertoy D; Argani P; Gupta S; Caliò A; Reuter V; Tickoo S; Al-Ahmadie HA; Netto GJ; Hes O; Hirsch MS; Delahunt B; Mehra R; Skala S; Osunkoya AO; Harik L; Rao P; Sangoi AR; Nourieh M; Zynger DL; Smith SC; Nazeer T; Gumuskaya B; Kulac I; Khani F; Tretiakova MS; Vakar-Lopez F; Barkan G; Molinié V; Verkarre V; Rao Q; Kis L; Panizo A; Farzaneh T; Magers MJ; Sanfrancesco J; Perrino C; Gondim D; Araneta R; So JS; Ro JY; Wasco M; Hameed O; Lopez-Beltran A; Samaratunga H; Wobker SE; Melamed J; Cheng L; Idrees MT
J Clin Pathol; 2021 May; 74(5):291-299. PubMed ID: 33514585
[TBL] [Abstract][Full Text] [Related]
5. Morphologic and Immunohistochemical Characteristics of Fluorescent In Situ Hybridization Confirmed TFE3-Gene Fusion Associated Renal Cell Carcinoma: A Single Institutional Cohort.
Akgul M; Saeed O; Levy D; Mann SA; Cheng L; Grignon DJ; Eble JN; Idrees MT
Am J Surg Pathol; 2020 Nov; 44(11):1450-1458. PubMed ID: 32701515
[TBL] [Abstract][Full Text] [Related]
6. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
[TBL] [Abstract][Full Text] [Related]
7. ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
Zhu Y; Liu N; Guo W; Pu X; Guo H; Gan W; Li D
Pathol Res Pract; 2020 Dec; 216(12):153286. PubMed ID: 33197836
[TBL] [Abstract][Full Text] [Related]
8. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
9. Minimally invasive cytologic evaluation leading to the diagnosis of TFE3-rearranged renal cell carcinoma: A case report.
Gama A; Sukhanova M; Choy B
Diagn Cytopathol; 2022 Dec; 50(12):E382-E385. PubMed ID: 35975764
[TBL] [Abstract][Full Text] [Related]
10. A novel VCP::TFE3 gene fusion resulting from t(X;9)(p11.23;p13.3) chromosome translocation in TFE3 rearranged renal cancer cell carcinoma.
Kuentz MA; Blons H; Gimenez-Roqueplo AP; Just PA; Laurent-Puig P; Mejean A; Oudard S; Verkarre V
Genes Chromosomes Cancer; 2023 Jun; 62(6):361-366. PubMed ID: 36695651
[TBL] [Abstract][Full Text] [Related]
11. A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.
Kurisaki-Arakawa A; Saito T; Takahashi M; Mitani K; Fukumura Y; Nagashima Y; Argani P; Yao T
Int J Clin Exp Pathol; 2013; 6(11):2585-90. PubMed ID: 24228124
[TBL] [Abstract][Full Text] [Related]
12. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
[TBL] [Abstract][Full Text] [Related]
13. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
[TBL] [Abstract][Full Text] [Related]
14. Computational analysis of pathological images enables a better diagnosis of TFE3 Xp11.2 translocation renal cell carcinoma.
Cheng J; Han Z; Mehra R; Shao W; Cheng M; Feng Q; Ni D; Huang K; Cheng L; Zhang J
Nat Commun; 2020 Apr; 11(1):1778. PubMed ID: 32286325
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
[No Abstract] [Full Text] [Related]
16. Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations.
Wang XM; Shao L; Xiao H; Myers JL; Pantanowitz L; Skala SL; Udager AM; Vaishampayan U; Mannan R; Dhanasekaran SM; Chinnaiyan AM; Betz BL; Brown N; Mehra R
Am J Clin Pathol; 2023 Dec; 160(6):549-554. PubMed ID: 37499055
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population.
Qu Y; Gu C; Wang H; Chang K; Yang X; Zhou X; Dai B; Zhu Y; Shi G; Zhang H; Ye D
Sci Rep; 2016 Feb; 6():21677. PubMed ID: 26880493
[TBL] [Abstract][Full Text] [Related]
18. A case of TFE3 translocation renal cell carcinoma with rare morphological features and literature review.
Xia T; Long H; Liao D; Wang W; Xiao X
Indian J Pathol Microbiol; 2023; 66(1):135-140. PubMed ID: 36656224
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study.
Sharain RF; Gown AM; Greipp PT; Folpe AL
Hum Pathol; 2019 May; 87():65-74. PubMed ID: 30851332
[TBL] [Abstract][Full Text] [Related]
20. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
